Structural analysis of the carboxy terminal PH domain of pleckstrin bound to D-myo-inositol 1,2,3,5,6-pentakisphosphate by Jackson, Sean G et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Structural Biology
Open Access Research article
Structural analysis of the carboxy terminal PH domain of pleckstrin 
bound to D-myo-inositol 1,2,3,5,6-pentakisphosphate
S e a nGJ a c k s o n 1, Yi Zhang2, Richard J Haslam1,2 and Murray S Junop*1
Address: 1Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Canada and 2Department of Pathology and 
Molecular Medicine, McMaster University, Hamilton, Canada
Email: Sean G Jackson - jacksosg@mcmaster.ca; Yi Zhang - zhangy3@ccf.org; Richard J Haslam - haslamr@mcmaster.ca; 
Murray S Junop* - junopm@mcmaster.ca
* Corresponding author    
Abstract
Background: Pleckstrin homology (PH) domains are one of the most prevalent domains in the
human proteome and represent the major phosphoinositide-binding module. These domains are
often found in signaling proteins and function predominately by targeting their host proteins to the
cell membrane. Inositol phosphates, which are structurally similar to phosphoinositides, are not
only known to play a role as signaling molecules but are also capable of being bound by PH domains.
Results: In the work presented here it is shown that the addition of commercial myo-inositol
hexakisphosphate (IP6) inhibited the binding of the carboxy terminal PH domain of pleckstrin (C-
PH) to phosphatidylinositol 3,4-bisphosphate with an IC50 of 7.5 µM. In an attempt to characterize
this binding structurally, C-PH was crystallized in the presence of IP6 and the structure was
determined to 1.35 Å. Examination of the resulting electron density unexpectedly revealed the
bound ligand to be D-myo-inositol 1,2,3,5,6-pentakisphosphate.
Conclusion: The discovery of D-myo-inositol 1,2,3,5,6-pentakisphosphate in the crystal structure
suggests that the inhibitory effects observed in the binding studies may be due to this ligand rather
than IP6. Analysis of the protein-ligand interaction demonstrated that this myo-inositol
pentakisphosphate isomer interacts specifically with protein residues known to be involved in
phosphoinositide binding. In addition to this, a structural alignment of other PH domains bound to
inositol phosphates containing either four or five phosphate groups revealed that the majority of
phosphate groups occupy conserved locations in the binding pockets of PH domains. These
findings, taken together with other recently reported studies suggest that myo-inositol
pentakisphosphates could act to regulate PH domain-phosphoinositide interactions by directly
competing for binding, thus playing an important role as signaling molecules.
Background
Pleckstrin is an intriguing platelet protein that appears to
be involved in reorganization of the cytoskeleton, as well
as attenuating various signaling pathways following plate-
let activation [1-6]. On cloning pleckstrin, two internal
repeats consisting of approximately 100 amino acids
including 30 identical residues were identified at the N-
and C-termini of the protein [7,8]. Similar regions were
later recognized in other proteins and these internal
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repeats were consequently termed pleckstrin homology
(PH) domains [9,10].
Since their first identification in pleckstrin, PH domains
have been found in over four hundred human proteins
(SMART database,[11]) making this domain one of the
most common in the human proteome. PH domain-con-
taining proteins are known to be involved in a number of
different cellular functions, including phosphoinositide
metabolism, protein phosphorylation and cytoskeletal
organization, suggesting that PH domains themselves
may also function in a variety of different ways (reviewed
in [12,13]). The crystal and solution structures of numer-
ous PH domains have been determined revealing that
despite sharing only low sequence similarity, they main-
tain a highly conserved fold. The domain structure con-
sists of a seven-stranded anti-parallel β-sandwich that is
closed at one end by a C-terminal alpha helix and remains
open at the other end, where several variable loop regions
are located (reviewed in [13]). Traditionally, PH domains
have been thought to function predominately as phosph-
oinositide-binding modules, targeting their host proteins
to the membrane where they can carry out their various
functions. The region known to bind these signaling lipids
has been identified as the variable β1–β2 loop, with some
PH domains contributing additional interacting residues
from nearby secondary structure elements. Despite their
early characterization as phosphoinositide-binding mod-
ules, it is now clear that the majority of PH domains do
not bind phosphoinositides with sufficient affinity or spe-
cificity to drive membrane localization [12], suggesting
that alternate functions are likely to exist for these
domains. In support of this notion, several reports have
shown that within some proteins, PH domains function
to mediate protein-protein interactions [14-16].
Given their wide distribution, it is likely that PH domains
mediate other processes in addition to protein-protein
interactions and membrane association through phosph-
oinositide-specific binding. In particular, it seems possi-
ble that specific soluble inositol phosphates (such as
inositol 1,4,5-trisphosphate[IP3]), could bind to PH
domains and thereby serve as important regulators [17].
Inositol phosphates are structurally very similar to the
phosphoinositide head groups known to bind to many
PH domains. In fact, it has been well established that PH
domains can bind inositol phosphates in vitro and have
been used extensively in structural and biochemical stud-
ies focused on understanding phosphoinositide-PH
domain interactions. Despite this they have received rela-
tively little consideration as physiological PH domain lig-
ands.
Previous studies have shown that phosphatidylinositol
3,4-bisphosphate [PtdIns(3,4)P2] binds to C-PH much
more firmly than other phosphoinositides [18,19] and
that IP6  is a potent inhibitor of pleckstrin-phosphoi-
nositide interactions [19]. Based on these findings, we
found that commercial IP6 also competed effectively with
PtdIns(3,4)P2 for binding to C-PH. As we have recently
reported the crystal structure of C-PH in the unliganded
form [20], we then set out to determine the structural
basis for the interaction with IP6. To our surprise, we
found that the complex formed contained D-myo-inositol
1,2,3,5,6-pentakisphosphate [Ins(1,2,3,5,6)P5], rather
than IP6. The structure presented here indicates that inosi-
tol polyphosphates can interact specifically with PH
domains and therefore lends further support to the idea
that at least some inositol phosphates may regulate PH
domain phosphoinositide association.
Results and Discussion
Addition of IP6 effectively competes for binding of 
PtdIns(3,4)P2 to C-PH
Using large unilamellar vesicles containing 5 mol%
PtdIns(3,4)P2, we found that simultaneous addition of
IP6  was able to prevent the binding of C-PH to
PtdIns(3,4)P2. As shown in Figure 1, the binding of C-PH
to PtdIns(3,4)P2 was markedly inhibited by addition of 10
µM IP6 and completely abolished by 100 µM IP6. Only
trace non-specific binding of C-PH to phosphatidylcho-
line was observed (Figure 1, lane 2). Using a range of IP6
concentrations, the apparent IC50 of the IP6 used was
determined to be 7.5 µM.
Structure of C-PH/ligand complex
To investigate further the nature of the myo-inositol
polyphosphate interaction with C-PH, crystals were pre-
Effects of IP6 on the Binding of C-PH to LUVs containing  PtdIns(3,4)P2 Figure 1
Effects of IP6 on the Binding of C-PH to LUVs con-
taining PtdIns(3,4)P2. C-PH binding to LUVs was tested as 
follows: lane 1, total C-PH added to incubations (0.3 µM); 
lane 2, C-PH bound to LUVs containing only phosphatidyl-
choline; lane 3, C-PH bound to LUVs also containing 5 mol% 
PtdIns(3,4)P2 ; lanes 4–7, as lane 3 with increasing concentra-
tions of IP6 (3, 10, 30 and 100 µM).
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pared using recombinant C-PH and IP6, which permitted
the determination of a high-resolution crystal structure.
Crystals of the complex were grown by the hanging drop
vapor diffusion method after incubation of C-PH with 1
mM IP6 (see materials and methods). The resulting crys-
tals were of exceptional quality and diffracted to 1.35 Å.
Data collection and model refinement statistics are pre-
sented in Table 1. The structure was solved by molecular
replacement using a search model based on the previously
determined C-PH crystal structure solved in the absence of
ligand (PDB code: 1ZM0). The final model (Figure 2) was
well ordered with the exception of an approximately
eight-residue loop region between the fifth and sixth beta
strands, corresponding to residues 303–310. Due to the
complete disorder of these residues they could not be
built into the final model. The overall structure of C-PH
containing bound ligand maintained the folding pattern
that is characteristic of the PH domain family. Thus, the
inositol phosphate ligand was found bound in a loop
region of C-PH formed between the first and second beta
strands which has been well-characterized in a number of
PH domains as the phosphoinositide binding region.
Examination of the electron density in this region
revealed that the bound D-myo-inositol polyphosphate
contained only 5 phosphate groups rather than the 6
found in IP6. Model building of the different possible D-
myo-inositol pentakisphosphates into the electron density
indicated the identity of the bound ligand to be
Ins(1,2,3,5,6)P5, as no other isomer fits the electron den-
sity. The identity of the bound ligand was determined
with a high degree of confidence, based on the high-reso-
lution data (1.35 Å), the well-ordered electron density in
the binding loop and the fact that only the phosphate at
the 2 position on the inositol ring adopts an axial confor-
mation. The presence of Ins(1,2,3,5,6)P5 was unexpected
as a commercial source of IP6 was used in the crystalliza-
tion experiments. However, if the IP6 sample contained
IP6 hydrolysis products this could account for the pres-
ence of Ins(1,2,3,5,6)P5 in the final C-PH structure. This
unexpected finding suggests that C-PH has a much higher
affinity for Ins(1,2,3,5,6)P5 than for IP6. In support of this
view, a separate study [21] showed that the IC50 for the
inhibition of binding of PtdIns(3,4)P2  to C-PH by
Ins(1,2,3,5,6)P5 was 2.2 µM. HPLC analysis of the IP6
sample used in these studies using a reverse-phase C18 col-
umn (Vydac 218TP54 RP column) revealed the IP6 sample
was in fact not pure. Conditions used to generate IP5-C-
PH co-crystals were mild and therefore not likely to have
resulted in conversion of IP6 to Ins(1,2,3,5,6)P5. Regard-
less of the source, Ins(1,2,3,5,6)P5  was found tightly
bound within the phosphoinositide binding pocket of C-
PH and provided important information on the binding
of D-myo-inositol polyphosphates to PH domains.
Analysis of the C-PH/Ins(1,2,3,5,6)P5 Complex
The final model of IP5-bound C-PH was determined at
exceptionally high resolution and consequently the inter-
actions observed between ligand and protein (Figure 3)
Table 1: Crystallographic and Data Refinement Statistics
C-PH/Ins(1,2,3,5,6)P5
Date Collection
Space group P212121
Unit-cell parameters (Å) a = 32.2, b = 47.7 and c = 64.1
α = β = γ = 90
No. of molecules in asymmetric unit 1
Resolution range (Å)a 32.03 – 1.35 (1.40–1.35)
Unique reflections 21 808
Data Redundancya 12.21 (7.17)
Completeness (%)a 97.7 (95.9)
I/σ(I)a 25.1 (3.9)
Rmerge(%)a 4.4 (45.4)
Model and refinement
Resolution range (Å)a 38.26 – 1.35 (1.39–1.35)
Rwork (%) 18.0
Rfree (%) 20.8
No. of reflections 20 722 (19 638 in working set and 1084 in test set)
Cutoff criterion
No. of amino acid residues/atoms 99/999
No. of waters 125
r.m.s.d bond lengths (Å) 0.034
r.m.s.d bond angles (°) 3.2
Average B factor (Å2) 23.2
PDB code 2I5F
aData for the highest resolution shell are shown in parentheses.BMC Structural Biology 2007, 7:80 http://www.biomedcentral.com/1472-6807/7/80
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can be reported with a high degree of certainty. Table 2
lists the specific interactions and distances observed
within the crystal structure between Ins(1,2,3,5,6)P5 and
C-PH. Ins(1,2,3,5,6)P5 was bound to C-PH in the β1–β2
loop region (residues 253–264 and 277), making numer-
ous interactions through all but one of its phosphate
groups (Figure 3). The only phosphate group that does
not interact with any residues of C-PH is that in the 1-
position of myo-inositol. Although exposed to solvent,
this phosphate remained ordered to the point of generat-
ing clear electron density. All amino acids that form stabi-
lizing interactions with Ins(1,2,3,5,6)P5 are located in the
β1–β2 loop region with the exception of Y277 which con-
tributes a hydrogen bond and is situated on the β3 strand
of C-PH. The 2-phosphate is the only phosphate that
adopts an axial position. This configuration is strongly
stabilized through interactions with the side chains of
R264 and K253. Unlike the 2-phosphate, the 3-phosphate
makes only a single interaction, in this case with Y277. As
already mentioned, the 4-phosphate is not present in the
structure. However the remaining 4-OH group, which rep-
resents the location where the additional phosphate
group of IP6 would be, does make an interaction with the
side chain of H256 at a distance of 3.5 Å. All attempts to
model in a phosphate group at this position resulted in
steric clashes with H256 and the main chain of residues
R257 or G255, depending on the position of the phos-
phate chosen. In addition, the electron density for H256
Overall crystal structure of C-PH bound to Ins(1,2,3,5,6)P5 Figure 2
Overall crystal structure of C-PH bound to Ins(1,2,3,5,6)P5. Cartoon representation of C-PH bound to Ins(1,2,3,5,6)P5. 
The phosphorous atoms of Ins(1,2,3,5,6)P5 are colored in yellow while the oxygen atoms are red. The loop region between the 
5th and 6th β-strands that could not be built into the model is shown by a broken line.BMC Structural Biology 2007, 7:80 http://www.biomedcentral.com/1472-6807/7/80
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is well-ordered indicating that this side chain is not
mobile and could not adopt a conformation that would
accommodate an additional phosphate group at the 4-
position. The 5-phosphate of Ins(1,2,3,5,6)P5 interacts
with main chain atoms of H256, R257 and N260 (water-
mediated), as well as the side chain of R257. The final
position on the inositol ring is occupied by the 6-phos-
phate and interacts with the side chain of R258 in addi-
tion to the main chain of N260 through a water molecule.
C-PH residues shown here to interact with
Ins(1,2,3,5,6)P5 are also known to be involved in binding
PtdIns(3,4)P2  [18]. This demonstrates that
Ins(1,2,3,5,6)P5 competes directly with PtdIns(3,4)P2 for
binding to C-PH. While it is not known exactly how
PtdIns(3,4)P2 interacts with residues in the binding loop,
it seems reasonable that two of the phosphates from
Ins(1,2,3,5,6)P5  will directly compete with the phos-
phates from PtdIns(3,4)P2  while the remaining phos-
phates will provide additional stabilizing interactions.
Comparison of the C-PH/Ins(1,2,3,5,6)P5 and Grp1/
Ins(1,3,4,5,6)P5 structures
Although the structure presented here represents the first
high resolution structure of Ins(1,2,3,5,6)P5 bound to a
Interactions between C-PH and Ins(1,2,3,5,6)P5 Figure 3
Interactions between C-PH and Ins(1,2,3,5,6)P5. A. and B. Two stereo views illustrating C-PH binding interactions with 
Ins(1,2,3,5,6)P5. Amino acid side chains and backbone atoms from C-PH making specific ligand contacts are indicated. The two 
water molecules mediating protein-ligand binding are shown as green balls.BMC Structural Biology 2007, 7:80 http://www.biomedcentral.com/1472-6807/7/80
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PH domain, the structure of another PH domain com-
plexed with Ins(1,3,4,5,6)P5 has been reported [22]. The
PH domain of Grp1 binds 3-phosphoinositides allowing
the protein to participate in regulating the actin cytoskel-
eton in response to phosphoinositide-3-kinase signaling
pathways. As such, the structure of the PH domain of
Grp1 complexed with Ins(1,3,4,5,6)P5 represents another
instance in which specific interactions of an inositol phos-
phate and the phosphoinositide binding cleft of a PH
domain might be expected to regulate the association of
the PH domain with a specific phosphoinositide. Com-
parison of the Grp1 PH domain complexed with
Ins(1,3,4,5,6)P5 (PDB code: 1FHW) with that of C-PH
bound to Ins(1,2,3,5,6)P5, revealed some intriguing simi-
larities and differences (Figure 4). Although both D-myo-
inositol pentakisphosphates are bound in the β1–β2 loop
region, they adopt slightly different orientations with
respect to their inositol rings (Figure 4). Remarkably,
despite this difference in the overall orientation of the
inositol ring, four of the five phosphate groups from each
ligand occupy overlapping positions in the β1–β2 binding
cleft. The 2-phosphate of Ins(1,2,3,5,6)P5 occupies the
same position as the 3-phosphate from Ins(1,3,4,5,6)P5.
In both structures, the phosphate group at this position
interacts with a highly conserved arginine residue (R264
in C-PH and R284 in Grp1). The arginine at this position
is conserved amongst a number of PH domains including
that of Bruton's tyrosine kinase (Btk), in which its muta-
tion to either histidine or proline causes the hereditary
immune disease X-linked agammaglobulinaemia [23]. In
the crystal structure of the Btk PH domain bound to
Ins(1,3,4,5)P4, it was shown that the conserved arginine
(R28) interacts with the 3-phosphate, suggesting that
mutation of this residue decreases the affinity of the PH
domain for its natural ligand, PtdIns(3,4,5)P3 [24].
The second overlapping phosphate position is occupied
by the 6 and 1-phosphates of Ins(1,2,3,5,6)P5  and
Ins(1,3,4,5,6)P5, respectively. In the C-PH structure, the 6-
phosphate interacts with R258, a residue that is not con-
Table 2: C-PH/Ins(1,2,3,5,6)P5 Interactions
Ins(1,2,3,5,6)P5 C-PH
Position Atom Interaction* Residue Atom Distance (Å)
1O 1 1 -
O21 -
O31 -
O41 -
2O 1 2 -
O22 + Arg-264 Nη2 2.7
O32 -
O42 + Arg-264 Nε 2.7
+ Lys-253 Nζ 2.8
3O 1 3 -
O23 -
O33 -
O43 + Tyr-277 Oη 2.5
4 O14 + His-256 Nδ1 3.5
5O 1 5 -
O25 + Arg-257 Nη2 3.2
O35 + His-256 N 3.1
O45 + His-256 N 3.2
+ Arg-257 N 2.7
+ Arg-257 Nε 3.0
6O 1 6 -
O26 + Arg-258 Nη2 3.1
O36 -
O46 -
*-, no interaction; +, interaction as shown.BMC Structural Biology 2007, 7:80 http://www.biomedcentral.com/1472-6807/7/80
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served in the Grp1 PH domain. The corresponding 1-
phosphate of Ins(1,3,4,5,6)P5 interacts with K282 in the
Grp1 PH domain which is equivalent to K262 in C-PH,
although this residue does not interact with the 6-phos-
phate of Ins(1,2,3,5,6)P5 due to the location of its side
chain. The 5-phosphate of Ins(1,2,3,5,6)P5 and the 6-
phosphate of Ins(1,3,4,5,6)P5 occupy the third overlap-
ping position within the phosphoinositide-binding
pocket. The 5-phosphate is in position to interact with the
main chains of H256, R257 and N260 as well as the side
chain of R257 in C-PH. Although this arginine is con-
served in the Grp1 PH domain (R277), it does not interact
with the 6-phosphate, in fact the 6-phosphate makes less
optimal interactions with main chain residues compared
to those observed in the C-PH structure. In the fourth and
final overlapping position, the 3-phosphate of
Ins(1,2,3,5,6)P5 and the 4-phosphate of Ins(1,3,4,5,6)P5
both interact with a conserved tyrosine at position 277 in
C-PH and 295 in the Grp1 PH domain. In addition to this,
the 4-phosphate makes further stabilizing contacts with
the side chains of H355 and K273, interactions that are
not observed in the C-PH/Ins(1,2,3,5,6)P5 structure.
From this structural comparison it can be seen that in
both cases the D-myo-inositol pentakisphosphate ligands
interact with conserved side chains that would be
involved in binding phosphoinositides. This suggests that
the D-myo-inositol pentakisphosphates would directly
compete with phosphoinositides for binding to the PH
domains. In addition to this, it was found that four out of
the five phosphates occupy overlapping positions within
the binding cleft despite the differences in orientation and
even stereochemistry. This overlap in phosphate positions
is not simply coincidence, since a structural alignment of
various PH domains solved in complex with either
Ins(1,3,4,5)P4 or the two D-myo-inositol pentakisphos-
phates used in the comparison above reveals that the over-
lapping positions are conserved in these structures as well
(Figure 5). The mode of interaction observed in our struc-
ture is therefore consistent with the possibility that myo-
inositol polyphosphates could act to regulate PH domain-
phosphoinositide associations by directly competing with
phosphoinositides for binding to PH domains.
D-myo-inositol pentakisphosphates as signaling molecules
The physiological significance of the interaction reported
here with respect to platelet signaling pathways is cur-
rently unknown and calls for further careful examination.
With the exception of IP3, inositol phosphates have only
been thought to function with minor roles as second mes-
sengers [25]. However, as more information becomes
available it appears as though these molecules have a
Structural comparison of the Grp1/Ins(1,3,4,5,6)P5 and C-PH/Ins(1,2,3,5,6)P5 structures Figure 4
Structural comparison of the Grp1/Ins(1,3,4,5,6)P5 and C-PH/Ins(1,2,3,5,6)P5 structures. Stereo view of structur-
ally superimposed Grp1/Ins(1,3,4,5,6)P5 and C-PH/Ins(1,2,3,5,6)P5. Grp1 and ligand, green; C-PH and ligand, grey. For simplicity 
a ribbon diagram for C-PH is shown.BMC Structural Biology 2007, 7:80 http://www.biomedcentral.com/1472-6807/7/80
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much broader role in signaling then was originally appre-
ciated [26,27]. The most well-characterized inositol phos-
phate second messenger is IP3, produced by
phospholipase C-mediated hydrolysis of PtdIns(4,5)P2.
In addition to IP3, it has also been proposed that
Ins(1,3,4,5)P4 plays a role in the regulation of cellular
Ca+2 fluxes [27]. The IP5 family of D-myo-inositol pentak-
isphosphates represents one of the most abundant forms
of inositol phosphates present in mammalian cells.
Although six possible isomers exist, Ins(1,3,4,5,6)P5 rep-
resents the predominant form observed in mammalian
cells, including platelets [27-30]. Other IP5  isomers
including Ins(1,2,4,5,6)P5 and Ins(2,3,4,5,6)P5 have been
detected in a number of cell lines [29,31], demonstrating
that these molecules are indeed present in mammalian
cells and as such could play roles in regulating biological
functions. In agreement with this, several recent studies
have provided evidence suggesting specific roles for IP5
isomers ranging from the regulation of chromatin remod-
eling [32,33] to Salmonella pathogenesis [34,35]. In fur-
ther support of this idea, Ins(1,3,4,5,6)P5 was recently
shown to be capable of promoting apoptosis and to pos-
sess antiangiogenic and antitumor effects as a result of its
ability to inhibit the phosphoinositide 3-kinase/Akt sign-
aling pathway [36,37]. This inhibition was shown to be a
consequence of Ins(1,3,4,5,6)P5  competing with
PtdIns(3,4,5)P3 for binding to the protein kinase B (Akt)
PH domain, ultimately preventing the phosphorylation
and activation of Akt. Based on these intriguing results the
authors have proposed that Ins(1,3,4,5,6)P5 and poten-
tially other inositol phosphates can be used as experimen-
tal or possibly therapeutic tools that interfere with the
binding of PH domains involved in signaling pathways.
Inositol pyrophosphates, specifically IP7 and IP8, have
also been shown to act as signaling molecules that regu-
late PH domain interactions with phosphoinositides [38].
In this study IP7 and IP8 were shown to compete with
PtdIns(3,4,5)P3 for binding to several PH domain-con-
taining proteins in Dictyostelium, resulting in an effect on
chemotaxis. As the body of evidence continues to grow, it
appears that PH domains will emerge as versatile domains
capable of mediating interactions with a range of different
ligands.
It therefore seems likely that as more studies are aimed at
examining the roles of IP5 isomers, it will become appar-
ent that this family of inositol phosphates is involved in
signaling pathways that affect a range of physiological
processes. The identification of PH domains capable of
interacting specifically with the various IP5 isomers will
aid in characterizing the roles of the latter. However, we
are not aware of any report of the presence of
Ins(1,2,3,5,6)P5 in platelets or other cells at the present
time. It will therefore be important to investigate the
effects of other IP5 isomers on the binding of pleckstrin C-
PH domain to PtdIns(3,4)P2. It has not escaped our atten-
tion that in addition to acting as antagonists of pleckstrin
binding by specific phosphoinositides, myo-inositol
polyphosphates with high affinities for C-PH could act as
regulators of the interaction of pleckstrin with other pro-
teins.
Conclusion
In the work presented here, the addition of commercial
IP6 was shown to compete with PtdIns(3,4)P2 for binding
to C-PH. Since Ins(1,2,3,5,6)P5 was found bound to C-PH
in the crystal structure it would appear that the inhibitory
effects observed in the binding studies were due to con-
tamination of IP6 with Ins(1,2,3,5,6)P5, which binds to C-
PH with a higher affinity. Regardless of its source,
Ins(1,2,3,5,6)P5  binds specifically in the phosphoi-
nositide binding cleft of C-PH making numerous interac-
tions with residues known to be involved in binding
PtdIns(3,4)P2[18]. In a structural comparison with the
Grp1 PH domain bound to Ins(1,3,4,5,6)P5  it was
observed that despite differences in their arrangement
Conserved binding positions of inositol phosphates to PH  domains Figure 5
Conserved binding positions of inositol phosphates to 
PH domains. Superimposed inositol phosphates in complex 
with PH domains from five different proteins: DAPP1/PHISH-
Ins(1,3,4,5)P4, red, 1FAO; Grp1-Ins(1,3,4,5)P4, yellow, 1FGY; 
ARNO-Ins(1,3,4,5)P4, blue, 1U27; Grp1-Ins(1,3,4,5,6)P5, 
green, 1FHW; C-PH-Ins(1,2,3,5,6)P5, gray, 2I5F. The four 
conserved phosphate binding positions are boxed.BMC Structural Biology 2007, 7:80 http://www.biomedcentral.com/1472-6807/7/80
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about the inositol ring, four out of the five phosphate
groups from these two ligands occupy conserved posi-
tions. This structural analysis, in combination with other
recently published data discussed above, suggests that
myo-inositol pentakisphosphates could act to regulate PH
domain-phosphoinositide interactions by directly com-
peting for binding to these domains. It is also possible
that myo-inositol pentakisphosphates could play roles in
signaling pathways by acting as inducers of protein-pro-
tein interactions.
Methods
C-PH binding assays
The binding assays were performed as described in [19].
Briefly, 0.3 µM recombinant C-PH was incubated with
large unilamellar vesicles (LUVs) consisting of phosphati-
dylcholine supplemented with 5 mol% PtdIns(3,4)P2.
Simultaneous additions of IP6 (Aldrich) (0–100 µM) were
used to inhibit the binding of C-PH to the PtdIns(3,4)P2.
LUVs with bound protein were isolated by ultracentrifuga-
tion, analyzed by SDS-PAGE using 10% acrylamide and
immunoblotted with antibody to the C-terminal 13 resi-
dues of pleckstrin. A logit plot was used to calculate the
apparent IC50 of IP6 (y = 100[1 + (x/IC50)s]-1, where y is the
% of added C-PH bound at the inhibitor concentration x
and s is a slope factor).
Protein expression and purification
C-PH (pleckstrin amino acids 240–350) used for LUV
binding studies was expressed and purified as described
previously [19,20]. For crystallography, C- and N-termi-
nal residues previously found to lack structure [20] were
omitted. Thus, the carboxy terminal PH domain (amino
acids 243–347) of human pleckstrin was expressed and
purified as a hexahistidine fusion protein in E. coli
BL21(DE3) cells using the pDEST17 expression vector
(Invitrogen). Cells were grown in standard LB medium
supplemented with 10 mg ml-1 ampicillin at 310 K with
shaking (225 rev min-1) until the light absorbance at 600
nm reached 0.5. Protein expression was then induced
using 0.1 mM IPTG and the incubation temperature was
lowered to 300 K. After a 5-hour induction period cells
were harvested by centrifugation at 4 000 rpm for 10 min-
utes at a temperature of 277 K. Each 1L cell pellet was then
resuspended in 8 ml of 1× phosphate buffered saline
(PBS) and centrifuged at 3 500 rpm for 10 minutes at 277
K. The resulting cell pellets were then frozen in liquid
nitrogen and stored at 193 K. Prior to cell lyses using high
pressure, cell pellets (2 L) were resuspended to a final vol-
ume of 35 ml using nickel A buffer (20 mM Hepes pH 7.5,
0.5 M NaCl, 0.06% LDAO, 2 mM β-mercaptoethanol and
10 mM imidazole). Following cell lyses samples were cen-
trifuged at 20 000 rpm for 40 minutes at 277 K and the
resulting supernatant was applied to a HiTrap Nickel
affinity column (Amersham Biosciences). The C-PH was
eluted from the column with 210 mM imidazole follow-
ing sequential washes with 15 and 30 mM imidazole
which was accomplished by mixing appropriate volumes
of nickel A buffer and nickel B buffer (20 mM Hepes pH
7.5, 0.5 M NaCl, 0.06% LDAO, 2 mM β-mercaptoethanol
and 300 mM imidazole). The protein sample was then
diluted in S-A buffer (10 mM Hepes pH 7.5, 1 mM dithi-
othreitol and 1 mM EDTA) to lower the salt concentration
to approximately 75 mM. This sample was then applied to
a HiTrap SP Sepharose HP ion exchange column (Amer-
sham Biosciences) to further purify the protein from any
remaining contaminants. The C-PH was subsequently
eluted using a gradient of increasing salt concentration
generated by the application of S-B buffer (10 mM Hepes
pH 7.5, 1 mM dithiothreitol, 1 mM EDTA and 0.5 M
NaCl). The hexahistidine tag was removed from the C-PH
by cleavage with TEV protease. This results in four residues
(Gly, Ser, Phe and Thr) being left N-terminal to the first
residue in C-PH. Of these four amino acids only the phe-
nylalanine and threonine residues could be reliably built
into the available electron density. In order to purify C-PH
from the cleaved hexahistidine tag and the TEV protease
the digested sample was re-applied to the HiTrap SP
Sepharose column and purified as described above. The
resulting C-PH sample was buffer exchanged into the final
crystallization buffer (5 mM pottasium glutamate, 120
mM sodium glutamate, 20 mM Hepes pH 7.5, 2.5 mM
EDTA, 2.5 mM EGTA and 3.15 mM MgCl2) using a HiPrep
26/10 Desalting column (Amersham Biosciences). The
resulting protein sample was concentrated to 4.0 mg ml-1
as determined by the Bradford assay, using a centrifugal
filter. SDS-PAGE analysis indicates that C-PH prepared by
this method is greater then 95% pure.
Crystallization and data collection of the C-PH/
Ins(1,2,3,5,6)P5 complex
C-PH (2.5 mg ml-1) was crystallized in the presence of 1
mM IP6 (Aldrich) using the hanging drop vapour diffu-
sion method under the following conditions. A 2 µl drop
containing 1 µl of C-PH (2.5 mg ml-1) and 1 mM IP6 in 5
mM potassium glutamate, 120 mM sodium glutamate, 20
mM Hepes pH 7.5, 2.5 mM EDTA, 2.5 mM EGTA and 3.15
mM MgCl2 and 1 µl of 0.1 M Bis-Tris pH 6.5 and 28% pol-
yethylene glycol 2 000 monomethyl ether was suspended
over 500 µl of 0.75 M ammonium sulfate and incubated
at 293 K. Rectangular rod-shaped crystals grown in these
conditions were harvested and crushed to generate micro-
nuclei that were subsequently used to streak seed into the
same crystallization condition as well as slight variations
of this condition. This resulted in large rectangular rod-
shaped crystals with dimensions of approximately 400 ×
100 × 100 µm. The crystal used to collect data was grown
in 0.1 M Bis-Tris pH 6.5 and 28% polyethylene glycol 2
000 monomethyl ether. Prior to cryocooling in a nitrogen
cold stream, the crystal was soaked for approximately 10BMC Structural Biology 2007, 7:80 http://www.biomedcentral.com/1472-6807/7/80
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seconds in a cryoprotectant containing 0.1 M Bis-Tris pH
6.5, 28% polyethylene glycol 2 000 monomethyl ether
and 17% glycerol. Both high (1.35 Å) and low (1.5 Å) res-
olution data sets were collected independently for this
crystal and then merged to yield a single data set. The data
was collected at a wavelength of 1.0 Å at beamline X25 of
the Brookhaven National Laboratory using a ADSC Q315
CCD x-ray detector and processed using the HKL2000
program suite [39].
Structure determination and model refinement
The crystal structure of the C-PH in complex with
Ins(1,2,3,5,6)P5  was solved by molecular replacement
using the program MOLREP [40]. The search model used
in molecular replacement was the crystal structure of the
C-PH (PDB code 1ZM0), which was solved in the absence
of any ligand. Iterative cycles of model building and
refinement were carried out using the programs WinCoot
[41] and Refmac5 [42,43] respectively. All figures describ-
ing protein structures presented were generated using the
molecular graphics program PyMol [44].
Authors' contributions
SGJ purified C-PH, crystallized the complex, collected and
processed crystallographic data, refined the structure and
prepared the manuscript. YZ purified C-PH and per-
formed the binding studies. RJH participated in designing
the study and preparing the manuscript. MSJ was involved
in designing and overseeing the study as well as preparing
the manuscript. All authors have read and approved the
final manuscript.
Acknowledgements
We wish to thank Dr. Kalinka Koteva for performing HPLC analysis to 
assess the purity of IP6. SGJ is a recipient of a CIHR Canada Graduate Schol-
arship Master's Award. This work was supported by independent grants to 
RJH and MSJ from CIHR.
References
1. Abrams CS, Wu H, Zhao W, Belmonte E, White D, Brass LF: Pleck-
strin inhibits phosphoinositide hydrolysis initiated by G-pro-
tein-coupled and growth factor receptors. A role for
pleckstrin's PH domains.  J Biol Chem 1995,
270(24):14485-14492.
2. Abrams CS, Zhang J, Downes CP, Tang X, Zhao W, Rittenhouse SE:
Phosphopleckstrin inhibits gbetagamma-activable platelet
phosphatidylinositol-4,5-bisphosphate 3-kinase.  J Biol Chem
1996, 271(41):25192-25197.
3. Auethavekiat V, Abrams CS, Majerus PW: Phosphorylation of
platelet pleckstrin activates inositol polyphosphate 5-phos-
phatase I.  J Biol Chem 1997, 272(3):1786-1790.
4. Ma AD, Brass LF, Abrams CS: Pleckstrin associates with plasma
membranes and induces the formation of membrane projec-
tions: requirements for phosphorylation and the NH2-termi-
nal PH domain.  J Cell Biol 1997, 136(5):1071-1079.
5. Ma AD, Abrams CS: Pleckstrin induces cytoskeletal reorgani-
zation via a Rac-dependent pathway.  J Biol Chem 1999,
274(40):28730-28735.
6. Roll RL, Bauman EM, Bennett JS, Abrams CS: Phosphorylated
pleckstrin induces cell spreading via an integrin-dependent
pathway.  J Cell Biol 2000, 150(6):1461-1466.
7. Tyers M, Rachubinski RA, Stewart MI, Varrichio AM, Shorr RG,
Haslam RJ, Harley CB: Molecular cloning and expression of the
major protein kinase C substrate of platelets.  Nature 1988,
333(6172):470-473.
8. Tyers M, Haslam RJ, Rachubinski RA, Harley CB: Molecular analysis
of pleckstrin: the major protein kinase C substrate of plate-
lets.  J Cell Biochem 1989, 40(2):133-145.
9. Haslam RJ, Koide HB, Hemmings BA: Pleckstrin domain homol-
ogy.  Nature 1993, 363(6427):309-310.
10. Mayer BJ, Ren R, Clark KL, Baltimore D: A putative modular
domain present in diverse signaling proteins.  Cell 1993,
73(4):629-630.
11. Letunic I, Copley RR, Pils B, Pinkert S, Schultz J, Bork P: SMART 5:
domains in the context of genomes and networks.  Nucleic
Acids Res 2006:D257-60.
12. Lemmon MA: Pleckstrin homology domains : not just for phos-
phoinositides.  Biochem Soc Trans 2004, 32(Pt 5):707-711.
13. Cozier GE, Carlton J, Bouyoucef D, Cullen PJ: Membrane target-
ing by pleckstrin homology domains.  Curr Top Microbiol Immunol
2004, 282:49-88.
14. Jezyk MR, Snyder JT, Gershberg S, Worthylake DK, Harden TK,
Sondek J: Crystal structure of Rac1 bound to its effector phos-
pholipase C-beta2.  Nat Struct Mol Biol 2006, 13(12):1135-1140.
15. Worthylake DK, Rossman KL, Sondek J: Crystal structure of the
DH/PH fragment of Dbs without bound GTPase.  Structure
2004, 12(6):1078-1086.
16. Lu M, Kinchen JM, Rossman KL, Grimsley C, deBakker C, Brugnera E,
Tosello-Trampont AC, Haney LB, Klingele D, Sondek J, Hengartner
MO, Ravichandran KS: PH domain of ELMO functions in trans
to regulate Rac activation via Dock180.  Nat Struct Mol Biol 2004,
11(8):756-762.
17. Philip F, Guo Y, Scarlata S: Multiple roles of pleckstrin homology
domains in phospholipase Cbeta function.  FEBS Lett 2002,
531(1):28-32.
18. Edlich C, Stier G, Simon B, Sattler M, Muhle-Goll C: Structure and
phosphatidylinositol-(3,4)-bisphosphate binding of the C-ter-
minal PH domain of human pleckstrin.  Structure 2005,
13(2):277-286.
19. Zhang Y: Studies of the functions of pleckstrin in blood plate-
lets : interactions of pleckstrin with phospholipids and solu-
ble platelet proteins.  I n  PhD Thesis McMaster University,
Department of Medical Sciences; 2005. 
20. Jackson SG, Zhang Y, Bao X, Zhang K, Summerfield R, Haslam RJ,
Junop MS: Structure of the carboxy-terminal PH domain of
pleckstrin at 2.1 Angstroms.  Acta Crystallogr D Biol Crystallogr
2006, 62(Pt 3):324-330.
21. Jackson SG, Zhang Y, Zhang K, Bao X, Schultz C, Haslam R, Junop M:
Structural analysis of the binding of myo-inositol pentaki-
sphosphates by the C-terminal PH domain of pleckstrin.
FASEB J 2007, 21(5):A629-a.
22. Ferguson KM, Kavran JM, Sankaran VG, Fournier E, Isakoff SJ, Skolnik
EY, Lemmon MA: Structural basis for discrimination of 3-phos-
phoinositides by pleckstrin homology domains.  Mol Cell 2000,
6(2):373-384.
23. Smith CI, Islam KB, Vorechovsky I, Olerup O, Wallin E, Rabbani H,
Baskin B, Hammarstrom L: X-linked agammaglobulinemia and
other immunoglobulin deficiencies.  Immunol Rev 1994,
138:159-183.
24. Baraldi E, Carugo KD, Hyvonen M, Surdo PL, Riley AM, Potter BV,
O'Brien R, Ladbury JE, Saraste M: Structure of the PH domain
from Bruton's tyrosine kinase in complex with inositol
1,3,4,5-tetrakisphosphate.  Structure 1999, 7(4):449-460.
25. Berridge MJ: Inositol trisphosphate and calcium signalling.
Nature 1993, 361(6410):315-325.
26. York JD, Guo S, Odom AR, Spiegelberg BD, Stolz LE: An expanded
view of inositol signaling.  Adv Enzyme Regul 2001, 41:57-71.
27. Irvine RF, Schell MJ: Back in the water: the return of the inositol
phosphates.  Nat Rev Mol Cell Biol 2001, 2(5):327-338.
28. Mayr GW: A novel metal-dye detection system permits pico-
molar-range h.p.l.c. analysis of inositol polyphosphates from
non-radioactively labelled cell or tissue specimens.  Biochem J
1988, 254(2):585-591.
29. Stephens LR, Hawkins PT, Stanley AF, Moore T, Poyner DR, Morris
PJ, Hanley MR, Kay RR, Irvine RF: myo-inositol pentakisphos-
phates. Structure, biological occurrence and phosphoryla-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Structural Biology 2007, 7:80 http://www.biomedcentral.com/1472-6807/7/80
Page 11 of 11
(page number not for citation purposes)
tion to myo-inositol hexakisphosphate.  Biochem J 1991, 275(Pt
2):485-499.
30. Shears SB: Metabolism of inositol phosphates.  Adv Second Mes-
senger Phosphoprotein Res 1992, 26:63-92.
31. McConnell FM, Stephens LR, Shears SB: Multiple isomers of inosi-
tol pentakisphosphate in Epstein-Barr-virus- transformed
(T5-1) B-lymphocytes. Identification of inositol 1,3,4,5,6-
pentakisphosphate, D-inositol 1,2,4,5,6-pentakisphosphate
and L-inositol 1,2,4,5,6-pentakisphosphate.  Biochem J 1991,
280(Pt 2):323-329.
32. Shen X, Xiao H, Ranallo R, Wu WH, Wu C: Modulation of ATP-
dependent chromatin-remodeling complexes by inositol
polyphosphates.  Science 2003, 299(5603):112-114.
33. Steger DJ, Haswell ES, Miller AL, Wente SR, O'Shea EK: Regulation
of chromatin remodeling by inositol polyphosphates.  Science
2003, 299(5603):114-116.
34. Zhou D, Chen LM, Hernandez L, Shears SB, Galan JE: A Salmonella
inositol polyphosphatase acts in conjunction with other bac-
terial effectors to promote host cell actin cytoskeleton rear-
rangements and bacterial internalization.  Mol Microbiol 2001,
39(2):248-259.
35. Deleu S, Choi K, Reece JM, Shears SB: Pathogenicity of Salmo-
nella: SopE-mediated membrane ruffling is independent of
inositol phosphate signals.  FEBS Lett 2006, 580(7):1709-1715.
36. Piccolo E, Vignati S, Maffucci T, Innominato PF, Riley AM, Potter BV,
Pandolfi PP, Broggini M, Iacobelli S, Innocenti P, Falasca M: Inositol
pentakisphosphate promotes apoptosis through the PI 3-K/
Akt pathway.  Oncogene 2004, 23(9):1754-1765.
37. Maffucci T, Piccolo E, Cumashi A, Iezzi M, Riley AM, Saiardi A, Godage
HY, Rossi C, Broggini M, Iacobelli S, Potter BV, Innocenti P, Falasca
M: Inhibition of the phosphatidylinositol 3-kinase/Akt path-
way by inositol pentakisphosphate results in antiangiogenic
and antitumor effects.  Cancer Res 2005, 65(18):8339-8349.
38. Luo HR, Huang YE, Chen JC, Saiardi A, Iijima M, Ye K, Huang Y,
Nagata E, Devreotes P, Snyder SH: Inositol pyrophosphates
mediate chemotaxis in Dictyostelium via pleckstrin homol-
ogy domain-PtdIns(3,4,5)P3 interactions.  Cell 2003,
114(5):559-572.
39. Otwinowski Z, Minor W: Processing of X-ray Diffraction Data
Collected in Oscillation Mode.  Methods in Enzymology 1997,
276(Macromolecular Crystallography, part A):307-326.
40. Vagin A, Teplyakov A: MOLREP: an automated program for
molecular replacement.  J Appl Cryst 1997, 30:1022-1025.
41. Emsley P, Cowtan K: Coot: model-building tools for molecular
graphics.  Acta Crystallogr D Biol Crystallogr 2004, 60(Pt 12 Pt
1):2126-2132.
42. Collaborative Computational Project, Number 4: The CCP4 suite :
programs for protein crystallography.  Acta Crystallogr D Biol
Crystallogr 1994, 50(Pt 5):760-763.
43. Murshudov GN, Vagin AA, Dodson EJ: Refinement of macromo-
lecular structures by the maximum-likelihood method.  Acta
Crystallogr D Biol Crystallogr 1997, 53(Pt 3):240-255.
44. The PyMOL Molecular Graphics System   [ h t t p : / /
www.pymol.org]